<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbed13734-tbl-0003" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
 <label>TABLE 3</label>
 <caption>
  <p>Vaccine candidates for SARS‐CoV‐2 in clinical trials and their current status in June 2020 based on clinicaltrials.gov, ISRCTN registry and Chinese clinical trial registry database</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="top">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="top" rowspan="1" colspan="1">Identifier</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Interventions</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Mechanism of action</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Status (Phase)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04400838</td>
    <td align="left" rowspan="1" colspan="1">ChAdOx1</td>
    <td align="left" rowspan="1" colspan="1">Non‐replicating viral vector</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04379336</td>
    <td align="left" rowspan="1" colspan="1">Bacille Calmette–Guérin (BCG)</td>
    <td align="left" rowspan="1" colspan="1">Enhancing non‐specific immune responses through Bacillus Calmette‐Guérin vaccination</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04412538</td>
    <td align="left" rowspan="1" colspan="1">Inactivated SARS‐CoV‐2</td>
    <td align="left" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04276896</td>
    <td align="left" rowspan="1" colspan="1">LV‐SMENP‐DC</td>
    <td align="left" rowspan="1" colspan="1">Lentiviral vector system (NHP/TYF) expressing viral proteins and immune modulatory genes to modify dendritic cells (DCs) and to activate T cells</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04383574</td>
    <td align="left" rowspan="1" colspan="1">Inactivated SARS‐CoV‐2</td>
    <td align="left" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04436471</td>
    <td align="left" rowspan="1" colspan="1">Adeno‐based</td>
    <td align="left" rowspan="1" colspan="1">Non‐replicating viral vector</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">ChiCTR2000031781</td>
    <td align="left" rowspan="1" colspan="1">Adenovirus Type 5 Vector</td>
    <td align="left" rowspan="1" colspan="1">Non‐replicating viral vector</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">ChiCTR2000031809</td>
    <td align="left" rowspan="1" colspan="1">Inactivated SARS‐CoV‐2</td>
    <td align="left" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" rowspan="1" colspan="1">I/II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">ChiCTR2000032459</td>
    <td align="left" rowspan="1" colspan="1">Inactivated SARS‐CoV‐2</td>
    <td align="left" rowspan="1" colspan="1">Inactivated</td>
    <td align="left" rowspan="1" colspan="1">I/II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04368988</td>
    <td align="left" rowspan="1" colspan="1">Recombinant Spike Protein</td>
    <td align="left" rowspan="1" colspan="1">SARS‐CoV‐2 Recombinant Spike Protein Nanoparticle vaccine (SARS‐CoV‐2 rS) with or without MATRIX‐M™ Adjuvant</td>
    <td align="left" rowspan="1" colspan="1">I/II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">ISRCTN17072692</td>
    <td align="left" rowspan="1" colspan="1">LNP‐nCoVsaRNA</td>
    <td align="left" rowspan="1" colspan="1">Self‐amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS‐CoV‐2</td>
    <td align="left" rowspan="1" colspan="1">I</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04368728</td>
    <td align="left" rowspan="1" colspan="1">3 LNP‐mRNAs</td>
    <td align="left" rowspan="1" colspan="1">Not mentioned</td>
    <td align="left" rowspan="1" colspan="1">I</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04405076</td>
    <td align="left" rowspan="1" colspan="1">mRNA‐1273</td>
    <td align="left" rowspan="1" colspan="1">Novel lipid nanoparticle (LNP)‐encapsulated mRNA‐based vaccine that encodes for a full‐length, spike (S) protein</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04313127</td>
    <td align="left" rowspan="1" colspan="1">Ad5‐nCoV</td>
    <td align="left" rowspan="1" colspan="1">Adenovirus type 5 vector that expresses S protein</td>
    <td align="left" rowspan="1" colspan="1">I</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04336410</td>
    <td align="left" rowspan="1" colspan="1">NO‐4800</td>
    <td align="left" rowspan="1" colspan="1">DNA plasmid encoding S protein delivered by electroporation</td>
    <td align="left" rowspan="1" colspan="1">I</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04299724</td>
    <td align="left" rowspan="1" colspan="1">Pathogen‐specific aAPC</td>
    <td align="left" rowspan="1" colspan="1">APCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins</td>
    <td align="left" rowspan="1" colspan="1">I</td>
   </tr>
  </tbody>
 </table>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
  <license>
   <license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
  </license>
 </permissions>
</table-wrap>
